Nicholas Barnes

Abstract Opioid analgesics remain essential for pain management but are associated with significant adverse effects, including respiratory depression, tolerance, and dependence. The δ-opioid receptor (δOR) represents a promising therapeutic target for developing safer opioid analgesics with reduced adverse effects compared to conventional μ-opioid receptor-targeting drugs.

Abstract Psychotic disorders, including schizophrenia and affective psychosis, affect ~3% of the population and typically emerge in early adulthood. Cardiometabolic disease accounts for much of the 20-year life-expectancy gap in psychosis. Evidence indicates potentially causal processes, often seen in aging, act within and beyond the brain, and before the onset of treatment; these include inflammation, metabolic and mitochondrial dysfunction.

Cannabis Pic/Shutterstock.com Once synonymous with hippies and hallucinatory experiences, psychedelic drugs are now being explored for their medical potential. The stigma of that era resulted in research being suppressed by drug laws, yet with mental health treatments hitting limits, scientists have returned to this controversial corner of medicine.